Abstract
Cannabidiol (CBD) is increasingly used for symptom relief in chronic conditions, yet its role in inflammatory bowel disease (IBD) remains underexplored. We surveyed 229 IBD patients and found that 10.5% used CBD, primarily for anxiety (54.2%), insomnia (41.7%), and pain (41.7%). Among users, 87.5% perceived benefit. Most users were female, and one-third were on biologics. These findings highlight the growing interest in alternative therapies and the need for further research on CBD's safety, efficacy, and clinical guidance in IBD care.